3.02
+1.319(+77.59%)
Currency In USD
| Previous Close | 1.7 |
| Open | 2.95 |
| Day High | 3.4 |
| Day Low | 2.64 |
| 52-Week High | 21.96 |
| 52-Week Low | 1.41 |
| Volume | 71.42M |
| Average Volume | 399,860 |
| Market Cap | 7.62M |
| PE | 5.73 |
| EPS | 0.51 |
| Moving Average 50 Days | 2.06 |
| Moving Average 200 Days | 2.18 |
| Change | 1.22 |
If you invested $1000 in VivoSim Labs, Inc. (VIVS) since IPO date, it would be worth $1,755.23 as of January 31, 2026 at a share price of $3.019. Whereas If you bought $1000 worth of VivoSim Labs, Inc. (VIVS) shares 0 years ago, it would be worth $1,755.23 as of January 31, 2026 at a share price of $3.019.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
GlobeNewswire Inc.
Jan 29, 2026 9:05 PM GMT
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevanceSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: V
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
GlobeNewswire Inc.
Jan 06, 2026 1:05 PM GMT
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platformsSAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Compan
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
GlobeNewswire Inc.
Aug 14, 2025 12:05 PM GMT
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing marketSAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceut